Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
The Swedish Orphan Biovitrum, or Sobi, has inked a licensing deal worth up to $580m with Innate Pharma for its…
10 Aug 2026
Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China. Under the contract, Daiichi Sankyo will continue to…
10 Aug 2026
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku for its investigational topical drug ENERGI-F703DFU to treat diabetic foot ulcers (DFUs). The collaboration will focus on process…
07 Aug 2026
Tarsus joins Stargardt race to market with $800m Alkeus takeover
Tarsus Pharmaceuticals has forged a takeover deal with Alkeus Pharmaceuticals worth up to $800m, adding a Stargardt disease asset with possible “blockbuster potential” to its pipeline and bolstering its standing…
07 Aug 2026
Context drops bispecific T-cell engager on cost-cutting initiative
Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the company looks to cut costs amid a dwindling cash runway.…
07 Aug 2026
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
Moderna has secured US Food and Drug Administration (FDA) approval for its mRNA influenza vaccine, overcoming initial data qualms from the agency and successfully navigating a wider US vaccine landscape…
07 Aug 2026
Evotec and Odyssey collaborate on AI-enabled R&D
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and inflammatory diseases. This collaboration will focus on utilising Evotec’s data-driven…